Search Results for: "amgen v tanvex filgrastim"

Another Biosimilar Litigation Settlement: Amgen v. Tanvex (Filgrastim)

Following last month’s dismissal of the Amgen v. Kashiv filgrastim biosimilar litigation, yesterday Amgen and Tanvex filed a joint stipulation of dismissal in their BPCIA litigation concerning Tanvex’s filgrastim biosimilar candidate. The stipulation states that the parties agree “to the dismissal, without prejudice, of all remaining claims and counterclaims in…

Read More

BPCIA Litigations

Pending U.S. District Court BPCIA Litigations Litigation Accused Biosimilar [status] Reference Product Complaint Filed Status/Outcome District Court Appeal Amgen v. Hospira, Nos. 18-1064, 20-561 (D. Del.) NIVESTYM (filgrastim-aafi) [approved] [launched] NEUPOGEN [litigation #4] July 18, 2018 Pending – jury trial scheduled for May 17, 2021 Immunex v. Samsung Bioepis, No….

Read More